Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

By Bolis G.   Parazzini F.   Scarfone G.   Villa A.   Amoroso M.   Rabaiotti E.   Polatti A.   Reina S.   Pirletti E.  

Gynecologic Oncology, Vol. 72, Iss. 1, 1999-01 ,pp. : 60-64

Elsevier

Access to resources Recommend Favorite

Treosulfan as an Effective Second-Line Therapy in Ovarian Cancer

By Gropp M.   Meier W.   Hepp H.  

Gynecologic Oncology, Vol. 71, Iss. 1, 1998-10 ,pp. : 94-98

Elsevier

Access to resources Recommend Favorite

Kinetic Modeling and Efficacy of Intraperitoneal Paclitaxel Combined with Intravenous Cyclophosphamide and Carboplatin as First-Line Treatment in Ovarian Cancer

By Hofstra L.S.   Bos A.M.E.   de Vries E.G.E.   van der Zee A.G.J.   Willemsen A.T.M.   Rosing H.   Beijnen J.H.   Mulder N.H.   Aalders J.G.   Willemse P.H.B.  

Gynecologic Oncology, Vol. 85, Iss. 3, 2002-06 ,pp. : 517-523

Academic Press

Access to resources Recommend Favorite

Intraperitoneal Cisplatin and Intravenous Paclitaxel in the Treatment of Epithelial Ovarian Cancer Patients with a Positive Second Look

By Makhija S.   Sabbatini P.   Aghajanian C.   Venkatraman E.   Spriggs D.R.   Barakat R.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 28-32

Elsevier

Access to resources Recommend Favorite

Five-Year Survival after Second-Line Cisplatin-Based Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

By Recio F.O.   Piver M.S.   Hempling R.E.   Driscoll D.L.  

Gynecologic Oncology, Vol. 68, Iss. 3, 1998-03 ,pp. : 267-273

Elsevier

Access to resources Recommend Favorite